FOXD2-AS1

Across TCGA pan-cancer cohorts, FOXD2-AS1 RNA differs between tumor and matched normal tissue in 17 of 18 cancer types tested, making tumor–normal expression one of FOXD2-AS1’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where FOXD2-AS1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types FOXD2-AS1 is over-expressed in tumor, although a few such as READ and KICH show the opposite, repressed pattern.

HNSC, KIRP, and BLCA are the cancer types where FOXD2-AS1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in FOXD2-AS1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	III,IV	+1.610	<.001	12	view →
KIRP	All	IV	+2.422	<.001	11	view →
BLCA	Male	All	+1.734	<.001	11	view →
THCA	Male	III,IV	+1.071	<.001	11	view →
KIRC	Female	All	+1.050	<.001	11	view →
STAD	Female	All	+2.348	<.001	10	view →
LUAD	Female	III,IV	+1.170	<.001	9	view →
LIHC	Female	All	+1.270	<.001	8	view →
LUSC	All	All	+0.875	<.001	7	view →
UCEC	All	III,IV	+1.128	.004	6	view →
BRCA	All	III,IV	+0.675	<.001	6	view →
CHOL	All	All	+2.312	<.001	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 17 lineages.

FOXD2-AS1–HNSC

Open the HNSC breakdown →